ClinicalTrials.gg
CompletedNCT07348237Updated Sep 15, 2026

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

A Phase 1 interventional study of MK-2828 in Chronic Kidney Failure, End-Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 24 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
24 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
6th of 12
18 · median 18
Started
2026
the only one that year
Phase 1
10 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2026, is one of 10 in phase 1, and was the 12th registered.

Kidney Failure, Chronic

2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 24 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.

03

Conditions studied

  • Chronic Kidney Failure
  • End-Stage Renal Disease
  • Renal Impairment
04

Who can participate

Ages eligible
24 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.

Severe Renal Impairment Participants:

  • Has an estimated (eGFR) \< 30 mL/min), but is not on hemodialysis (HD)

ESRD on HD Participants:

  • Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for > 3 months prior to study entry

The main exclusion criteria include but are not limited to the following:

Renal Impairment Participants:

  • History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.

Healthy Matched Control Participants:

  • History of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment will receive a single dose of MK-2828 on Day 1

    Drug: MK-2828

  • Experimental
    End Stage Renal Disease (ESRD) on Hemodialysis (HD)

    Participants with ESRD will receive a single dose of MK-2828 on Day 1 in each of 2 periods, with a washout of at least 14 days between doses.

    Drug: MK-2828

  • Experimental
    Healthy Mean Matched Control

    Participants with normal renal function will receive a single dose of MK-2828 on Day 1

    Drug: MK-2828

Interventions

  • DrugMK-2828

    Oral administration

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma

    Blood samples will be collected to determine the AUC0-inf of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  2. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of MK-2828 in Plasma

    Blood samples will be collected to determine the AUC0-last of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  3. Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of MK-2828 in Plasma

    Blood samples will be collected to determine the AUC0-24 of MK-2828

    Time frame: Pre dose and at designated time points up to 24 hours post dose

  4. Maximum Plasma Concentration (Cmax) of MK-2828 in Plasma

    Blood samples will be collected to determine the Cmax of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  5. Time of the Maximum Observed Concentration (Tmax) of MK-2828 in Plasma

    Blood samples will be collected to determine the Tmax of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  6. Concentration at 24 Hours Postdose (C24) of MK-2828 in Plasma

    Blood samples will be collected to determine the C24 of MK-2828

    Time frame: At designated time points up to 24 hours post dose

  7. Apparent Terminal Elimination Half-life (t1/2) of MK-2828 in Plasma

    Blood samples will be collected to determine the t1/2 of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  8. Apparent Total Plasma Clearance (CL/F) of MK-2828

    Blood samples will be collected to determine the CL/F of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

  9. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of MK-2828 in Plasma

    Blood samples will be collected to determine the Vz/F of MK-2828

    Time frame: Pre dose and at designated time points up to 192 hours post dose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 14 days

  2. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 2 days

  3. Area Under the Concentration-time Curve From Start to End of Dialysis (AUCD) of MK-2828

    Blood samples will be collected to determine the AUCD of MK-2828

    Time frame: Prior to hemodialysis (HD) and at designated time points until day 6

  4. Area Under the Concentration-time Curve Determined from the Pre-dialyzer Line (AUCCa) of MK-2828

    Blood samples will be collected to determine the during AUCCa of MK-2828 during the dialysis period

    Time frame: Prior to hemodialysis (HD) and at designated time points until day 6

  5. Area Under the Concentration-time Curve Determined from the Post-dialyzer Line (AUCCv) of MK-2828

    Blood samples will be collected to determine the during AUCCv of MK-2828 during the dialysis period

    Time frame: Prior to hemodialysis (HD) and at designated time points until day 6

  6. Dialysis Clearance (CLD) of MK-2828 Based on Plasma

    Blood samples will be collected to determine the CLD of MK-2828 based on plasma during the dialysis period

    Time frame: Prior to hemodialysis (HD) and at designated time points until day 6

  7. Hemodialysis Extraction Ratio (ER_D) of MK-2828

    Blood samples will be collected to determine the ER\_D of MK-2828 during the dialysis period

    Time frame: Prior to hemodialysis (HD) and at designated time points until day 6

07

Study locations

3 sites
  • Panax Clinical Research ( Site 0003)
    Miami Lakes, Florida 33014, United States
  • Floridian Clinical Research ( Site 0001)
    Miami Lakes, Florida 33016, United States
  • Orlando Clinical Research Center ( Site 0002)
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Sep 2026, 5 months.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Mar 2, 2026
Primary completionActual
Sep 1, 2026
CompletionActual
Sep 1, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07348237
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Mar 2, 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Sep 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion